View Older Stories

Sep 10, 2025 06:01AM Kadimastem and NLS Pharmaceutics clear SEC hurdle for merger

Sep 4, 2025 07:39AM Kadimastem receives Hong Kong patent for diabetes therapy technology

May 21, 2025 07:30AM NLS Pharmaceutics (NLSP) to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

Apr 15, 2025 09:02AM NLS Pharmaceutics (NLSP) announces positive results from KO-943 study on Mazindol efficacy

Mar 31, 2025 09:12AM NLS Pharmaceutics (NLSP) and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

Mar 31, 2025 09:10AM NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

Mar 10, 2025 07:04AM NLS Pharmaceutics (NLSP) CEO Issues Letter to Shareholders

Feb 27, 2025 07:05AM NLS Pharmaceutics (NLSP) Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Feb 10, 2025 07:31AM NLS Pharmaceutics (NLSP) and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Jan 31, 2025 07:31AM Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (NLSP)

Jan 30, 2025 07:32AM NLS Pharmaceutics (NLSP) Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

Jan 28, 2025 07:32AM NLS Pharmaceutics (NLSP) Launches a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

Dec 30, 2024 07:31AM NLS Pharmaceutics (NLSP) and Kadimastem Files F-4 Registration Statement with the SEC Ahead of Proposed Merger

Dec 19, 2024 07:31AM NLS Pharmaceutics (NLSP) and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance for FDA Pre-IND Meeting

Dec 19, 2024 07:30AM NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

Dec 11, 2024 07:32AM NLS Pharmaceutics (NLSP) CEO Issues Letter to Shareholders

Dec 11, 2024 07:30AM NLS Pharmaceutics CEO Issues Letter to Shareholders

Dec 4, 2024 01:15PM NLS Pharmaceutics (NLSP) Prices 322.58K Share Offering at $3.10/sh

Dec 3, 2024 07:41AM NLS Pharmaceutics (NLSP) Reports Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists

Dec 3, 2024 07:40AM NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders

Nov 18, 2024 07:30AM NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders

Nov 4, 2024 07:03AM NLS Pharmaceutics (NLSP) to Merge with Kadimastem

Nov 4, 2024 07:00AM NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

Oct 28, 2024 07:02AM NLS Pharmaceutics (NLSP) Regains Nasdaq Compliance

Oct 28, 2024 07:00AM NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements

Oct 21, 2024 07:03AM NLS Pharmaceutics (NLSP) Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

Oct 21, 2024 07:00AM NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

Oct 15, 2024 07:00AM NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules

Sep 25, 2024 08:04AM NLS Pharmaceutics (NLSP) Announces Expected Implementation of 1-for-40 Reverse Share Split

Sep 25, 2024 08:00AM NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

Jul 29, 2024 07:02AM NLS Pharmaceutics (NLSP) and Kadimastem Announce Binding Term Sheet to Merge

Jul 29, 2024 07:00AM NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

Jul 29, 2024 06:57AM NLS Pharmaceutics (NLSP) Halted, News Pending

Jun 28, 2024 09:02AM NLS Pharmaceutics (NLSP) Announces 3.28M Share Offering at $0.24/sh

Jun 28, 2024 09:00AM NLS Pharmaceutics Announces Registered Direct Offering

Jun 27, 2024 08:45AM NLS Pharmaceutics (NLSP) Announces Promising Preclinical Results for Parkinson's Disease Treatments

Jun 27, 2024 08:07AM NLS Pharmaceutics (NLSP) Reports Promising Preclinical Results for Parkinson's Disease Treatments

Jun 27, 2024 08:00AM NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Jun 27, 2024 08:00AM NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Jun 27, 2024 08:00AM NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments

Jun 25, 2024 09:13AM NLS Pharmaceutics (NLSP) Granted Nasdaq Extension to Regain Compliance

Jun 25, 2024 08:30AM Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements

Jun 11, 2024 08:32AM NLS Pharmaceutics (NLSP) Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists

Jun 11, 2024 08:30AM NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)

View Older Stories